These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 25670505)

  • 41. [Adverse events related to substitution of generic products in Norway 2005].
    Reppe LA; Stenberg-Nilsen H; Harg P; Hegge AB; Lillefloth AK; Buajordet I
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2696-700. PubMed ID: 19079413
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The future of population-based postmarket drug risk assessment: a regulator's perspective.
    Hammad TA; Neyarapally GA; Iyasu S; Staffa JA; Dal Pan G
    Clin Pharmacol Ther; 2013 Sep; 94(3):349-58. PubMed ID: 23739537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014.
    Moore TJ; Furberg CD; Mattison DR; Cohen MR
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):713-8. PubMed ID: 26861066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases.
    Avillach P; Salvo F; Thiessard F; Miremont-Salamé G; Fourrier-Reglat A; Haramburu F; Bégaud B; Moore N; Pariente A;
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):186-94. PubMed ID: 23670805
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution.
    Mott DA; Cline RR
    Med Care; 2002 Aug; 40(8):662-74. PubMed ID: 12187180
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nutravigilance: principles and practices to enhance adverse event reporting in the dietary supplement and natural products industry.
    Schmitz SM; Lopez HL; MacKay D
    Int J Food Sci Nutr; 2014 Mar; 65(2):129-34. PubMed ID: 24112316
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs.
    Perucca E; Albani F; Capovilla G; Bernardina BD; Michelucci R; Zaccara G
    Epilepsia; 2006; 47 Suppl 5():16-20. PubMed ID: 17239100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.
    Johann-Liang R; Wyeth J; Chen M; Cope JU
    Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):24-7. PubMed ID: 19009550
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility.
    Muñoz MA; Dal Pan GJ; Wei YJ; Delcher C; Xiao H; Kortepeter CM; Winterstein AG
    Drug Saf; 2020 Apr; 43(4):329-338. PubMed ID: 31912439
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparing reporting rates of adverse events between drugs with adjustment for year of marketing and secular trends in total reporting.
    Tsong Y
    J Biopharm Stat; 1995 Mar; 5(1):95-114. PubMed ID: 7613562
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System.
    Marwitz K; Jones SC; Kortepeter CM; Dal Pan GJ; Muñoz MA
    Drug Saf; 2020 May; 43(5):457-465. PubMed ID: 31981082
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A survey exploring knowledge and perceptions of general practitioners towards the use of generic medicines in the northern state of Malaysia.
    Chua GN; Hassali MA; Shafie AA; Awaisu A
    Health Policy; 2010 May; 95(2-3):229-35. PubMed ID: 20044165
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration.
    Muñoz MA; Delcher C; Dal Pan GJ; Kortepeter CM; Wu E; Wei YJ; Xiao H; Winterstein AG
    Pharmacotherapy; 2019 Nov; 39(11):1042-1052. PubMed ID: 31479525
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports.
    Klein K; Scholl JH; Vermeer NS; Broekmans AW; Van Puijenbroek EP; De Bruin ML; Stolk P
    Drug Saf; 2016 Feb; 39(2):185-92. PubMed ID: 26719190
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dispensing pattern of generic and brand-name drugs in children.
    Chen AY; Wu S
    Ambul Pediatr; 2008; 8(3):189-94. PubMed ID: 18501866
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Evaluation of the Association of Hand-Foot Syndrome with Anticancer Drugs Using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) Databases].
    Sasaoka S; Matsui T; Abe J; Umetsu R; Kato Y; Ueda N; Hane Y; Motooka Y; Hatahira H; Kinosada Y; Nakamura M
    Yakugaku Zasshi; 2016; 136(3):507-15. PubMed ID: 26935094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lack of essential information in spontaneous reports of adverse drug reactions in Catalonia-a restraint to the potentiality for signal detection.
    Plessis L; Gómez A; García N; Cereza G; Figueras A
    Eur J Clin Pharmacol; 2017 Jun; 73(6):751-758. PubMed ID: 28251276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.